



Announcement Summary

Entity name

ISLAND PHARMACEUTICALS LIMITED

Date of this announcement

Tuesday December 17, 2024

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
ILAAL	OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	6,000,000	10/12/2024

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

ISLAND PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

48641183842

1.3 ASX issuer code

ILA

1.4 The announcement is

New announcement

1.5 Date of this announcement

17/12/2024



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

ILAAL : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

Date the +securities the subject of this notification were issued

10/12/2024

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
David Foster	David Foster	4,000,000
Christopher Ntoumenopoulos	Christopher Ntoumenopoulos	2,000,000

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

<https://www.islandpharmaceuticals.com/site/pdf/b1626b2f-6009-4e96-8105-279dcb2c8e71/Letter-to-Shareholders-Notice-of-AGM-Proxy-Form.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

Approved at Annual General meeting held on 19 November 2024 (Resolution 10 & Resolution 14).

Issue details

Number of +securities

6,000,000



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
ILA : ORDINARY FULLY PAID	180,758,317
ILAO : OPTION EXPIRING 14-MAR-2025	29,397,636

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
ILAAM : OPTION EXPIRING 28-APR-2026 EX \$0.21	1,380,000
ILAAP : OPTION EXPIRING 04-DEC-2025 EX \$0.07	25,000,000
ILAAQ : OPTION EXPIRING 04-DEC-2026 EX \$0.07	25,000,000
ILAAO : OPTION EXPIRING 21-MAR-2027 EX \$0.12	3,617,500
ILAAL : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	6,203,802



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

Yes

5.2a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

19/11/2024